secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265707
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q3 net loss narrows to $13.9M; cash $117.6M supports ops into 2028
--------------------------------------------------------------------------------

- Net loss of $13.9M vs $16.5M in Q3 2024; R&D expenses $10.7M (down 24% YoY).
- Cash, cash equivalents and short-term investments of $117.6M as of Sept 30, 2025.
- Enrollment ongoing in BBI-355/BBI-825 combination arm of POTENTIATE trial.
- IND submission for BBI-940 on track; Phase 1 trial expected in H1 2026.
- Cash runway into first half of 2028 through proof-of-concept clinical readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/0001193125-25-265707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/bold-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer